LUCIER PHARMACEUTICALS INC
Raised
Pre-open
Investors
3
Min Invest
$10,000
AltStreet Analysis
·Generated from EDGAR primary sources
Lucier Pharmaceuticals Inc, a Texas-incorporated company, filed a Form D under the 506(b) exemption on 2026-10-13, reporting 3 investors and a $10,000 minimum investment. The total amount sold is not disclosed (filing appears pre-open), and the securities are classified as 'Other' rather than a standard equity or debt type. This is a standalone filing with no identified parent platform or related fund family.
This filing follows the common Rule 506(b) private-placement pattern used by early-stage operating companies raising capital from a small number of investors, consistent with the $10K minimum check size and limited investor count (3) typical of pre-institutional rounds. The 'Other' securities designation and lack of disclosed proceeds distinguish it from more standardized common-stock or fund-unit offerings seen elsewhere in the alternative investment space.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Oct 13, 2026
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
pre_sale
Latest event New filer · Oct 13, 2026
SEC.govInvestor
- 1 filing event with values and deltas, latest 2026-10-13, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Guangrong Lu Lu
Executive Officer · Cypress, TX
Questions About LUCIER PHARMACEUTICALS INC
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is LUCIER PHARMACEUTICALS INC?
LUCIER PHARMACEUTICALS INC is a Texas corporation organized in 2023 that filed a Form D with the SEC on October 13, 2026 in the Pharmaceuticals industry group. The filing claims Rule 506(b).
Is LUCIER PHARMACEUTICALS INC legit?
AltStreet does not rate legitimacy; it reports the public record. LUCIER PHARMACEUTICALS INC filed a Form D with the SEC on October 13, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. No sales had been reported as of that notice. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is LUCIER PHARMACEUTICALS INC registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that LUCIER PHARMACEUTICALS INC claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has LUCIER PHARMACEUTICALS INC raised?
LUCIER PHARMACEUTICALS INC reported that the first sale had not yet occurred as of the Form D filed October 13, 2026, so no amount sold or investor count is on file. The total offering amount is $2,000,000.
Who can invest in LUCIER PHARMACEUTICALS INC?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports 3 non-accredited investors. The minimum investment accepted from an outside investor is $10,000.
What is the minimum investment in LUCIER PHARMACEUTICALS INC?
The Form D lists $10,000 as the minimum investment accepted from any outside investor as of October 13, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling LUCIER PHARMACEUTICALS INC and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind LUCIER PHARMACEUTICALS INC?
The Form D lists 1 related person: Guangrong Lu Lu, executive officer (CEO and the issuer is the same person. Lcuier was originally registered at his home address. New business address is in Bryan, TX recently). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is LUCIER PHARMACEUTICALS INC located?
The issuer's address on its SEC filings is 3608 E. 29th Street, Suite 209, Bryan, TX 77802. Its phone number of record is 2817778730. It is organized under the laws of Texas.
How long is the LUCIER PHARMACEUTICALS INC offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is LUCIER PHARMACEUTICALS INC's revenue?
The Form D reports a revenue range of $1 - $1,000,000.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.